RxDoctor Payments Data

Juan Alarcon, MD

Urology · Montebello, CANPI 1609834217

Payments from drug & device makers

$57,529in general payments, 2019–2025

Across 301 payments — averaging $191.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$30K
  • Coloplast$20K
  • Pfizer$947
  • SN Holdings, LLC$868
  • Astellas Pharma US Inc$802
  • Sumitomo Pharma America, Inc.$646
  • plus $4K from 29 others

What the payments were for

  • Grants$1210%
  • Travel & lodging$4352%
  • Food & beverage$7,00026%
  • Education$19,70672%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$57,529 in reported general payments places this provider in the 85th percentile of 1,324 urology providers in California.

See all urology providers in California

Medicare billing

Part B allowed, 2024
$231,069
Medicare patients
530
Services billed
2,196

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide45$721,538
Lupron DepotLeuprolide Acetate61$703,858
GemtesaVibegron289$240,925
MyrbetriqMirabegron144$112,674
Tamsulosin Hcl1,491$27,553
Finasteride933$12,517
Silodosin12$2,429
Dutasteride52$2,204
Oxybutynin Chloride156$1,757
Bicalutamide41$1,645
Oxybutynin Chloride ErOxybutynin Chloride70$1,535
Ciprofloxacin Hcl575$1,456
Solifenacin Succinate12$1,352
Estradiol25$1,208
Alfuzosin Hcl ErAlfuzosin Hcl30$663

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$802$834,212189 claims
AbbVieLupron Depot$28$703,85861 claims
Sumitomo Pharma America, Inc.Gemtesa$646$240,925289 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,324 urology providers in California.

Other urology in Montebello

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →